Overview

Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
1st-line treatment of HER2/neu overexpressing breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Collaborator:
Pierre Fabre Laboratories
Treatments:
Trastuzumab
Vinblastine
Vinorelbine